June 10, 2025
Studying the Clinical Impact of Restoring Native Flow
This three part webinar series is presented by: Drs. Martin B. Leon, Tsuyoshi Kaneko, Brian Lindman, and Jeffrey Popma.
Annual General Meeting 2024
The recording of our Annual General Meeting is now available for viewing. This comprehensive session includes detailed discussions, strategic updates, and future plans that underscore the continued growth and innovation at Anteris Technologies.
Subscribe to our newsletter and stay up to date on features and releases.
By subscribing you agree to with our Privacy Policy and provide consent to receive updates from our company.
The Importance of Laminar Flow in TAVR
In this whitepaper, we review the pathophysiology of aortic stenosis—including upstream and downstream consequences of turbulent flow—and offer hypotheses around the impacts of TAVR design on flow patterns and disease regression.
We will explore answers to questions like:
- How do flow patterns impact the cardiovascular system?
- Does valve design impact flow patterns?
DurAVR® THV Clinical Data Update at Sydney Valves
At Sydney Valves, Dr. Rishi Puri presented data from DurAVR® THV clinical experience, demonstrating a favorable hemodynamic profile for 37 patients sustained to 1-year follow-up.
One-year Results Highlights:
- DurAVR® THV demonstrated a favorable hemodynamic profile sustained to one-year, with an Effective Orifice Area (EOA) of 2.1 ± 0.2 cm2, a Mean Pressure Gradient (MPG) of 8.6 ± 2.6 mmHg and Doppler Velocity Index (DVI) of 0.58.
- At one-year, clinical safety outcomes show positive results with no valve or cardiovascular related mortality and, importantly, no prosthesis-patient mismatch (PPM) reported in these small annuli patients (aortic annulus area 395.80 ± 37.26mm2).
“The one-year data for DurAVR® THV continues to validate its groundbreaking hemodynamic performance, demonstrating sustained excellent effective orifice area (EOA) and low mean gradients. Most notably, this is the only transcatheter valve to show zero prosthesis-patient mismatch (PPM) in small annuli patients—an achievement that sets a new standard in TAVR. PPM is a well-established predictor of valve failure and disease progression, and eliminating it has profound implications for long-term patient outcomes. These results reinforce the transformative potential of DurAVR® as we move toward pivotal trials.” - Christopher Meduri, Anteris Chief Medical Officer
MRI Data Update on First-in-Human Study at TCT 2024
At TCT 2024, Dr. Amar Krishnaswamy presented the latest MRI data analyses which compared flow dynamics and left ventricular function between DurAVR® THV recipients and a matched healthy control group. Here were some of the key takeaways:
In this matched analysis, DurAVR® THV’s biomimetic design provides flow patterns similar to the healthy valve, as measured by flow displacement (FD) and flow reversal ratios (FRR).
LV mass decreased in patients treated with DurAVR® THV compared to baseline, suggesting an improvement in LV unloading.
In this matched analysis, DurAVR® THV restored left ventricle (LV) end-diastolic volume, LV end-systolic volume, and LV mass to similar to healthy controls.
MRI Data Update on First-in-Human Study at London Valves
At London Valves 2024, Dr. Pankaj Garg presented cutting-edge cardiac MRI analyses, which compared flow dynamics and LV function between DurAVR® THV recipients and a healthy control group. These promising data highlight the potential of DurAVR® THV to mimic the performance of a healthy aortic valve as a result of the valve's biomimetic design.
TCT 2024 Physician Panel Interview
Drs. Amar Krishnaswamy, Nicolas Van Mieghem, and Bernard Prendergast review the latest DurAVR® THV MRI flow & LV mass data compared to a healthy control group, exploring the impact of valve design on laminar flow, disease regression, and patient outcomes.
Data Update on First-in-Human Study at New York Valves
We are pleased to announce new DurAVR® THV First-in-Human study data was presented at New York Valves by imaging expert Dr. João Cavalcante. “When we look at commercially available surgical or TAVR valves, we are still seeing abnormal flow patterns on cardiac MRI. The restoration of laminar flow, as we are seeing with this new DurAVR® THV, is a byproduct of the intrinsic valve design and novel technology, which might have positive downstream implications to the arteries and consequently to ventricle, and ultimately to the patients,” stated Dr. Cavalcante.
